Skip to content

Study · Animal study (in vivo) · mouse · 2018

2 results

Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice.

Stark C, Taimen P, Savunen T, Koskenvuo J

BMC research notes21 Feb 2018Cited by 15 (Europe PMC)

PMID29467032 (opens in a new tab)PMCIDPMC5822632 (opens in a new tab)DOI10.1186/s13104-018-3260-6 (opens in a new tab)PepBankPUB-29467032
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

ObjectiveWe wanted to determine the impact of different doses of a pegylated and liposomal formulation of the cardiotoxic drug doxorubicin on cardiac function, fibrosis and survival in mice. The drug causes myocardial damage by producing reactive oxygen species, mitochondrial damage and lipid peroxidation. Thymosin beta 4 is a peptide with cardioprotective, anti-oxidant and anti-fibrotic properties and we further investigated whether the peptide could attenuate this drug-induced injury by measuring cardiac function and fibrosis.ResultsMice receiving high doses of doxorubicin died early during follow-up. Lowering the dose improved survival but did not markedly impair cardiac function on echocardiography and caused only limited fibrosis on histology. Thymosin beta 4 had only a mild protective effect on early cardiac function and did not significantly influence myocardial fibrosis. In conclusion, the use of pegylated and liposomal doxorubicin was not appropriate for inducing experimental cardiomyopathy. Thymosin beta 4 therapy was not beneficial in this setting.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice given pegylated liposomal doxorubicin, Tβ4 had only a mild protective effect on early cardiac function.

    In plain wordsIn mice with drug-induced heart injury, Tβ4 had only a mild protective effect on early heart function.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseEarly cardiac function on echocardiography
    Study

    mousen: not reported in source

    mice with doxorubicin-induced cardiac injury
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin beta 4 had only a mild protective effect on early cardiac function and did not significantly influence myocardial fibrosis.
    1 context sentence
    Summary · context
    Thymosin beta 4 is a peptide with cardioprotective, anti-oxidant and anti-fibrotic properties and we further investigated whether the peptide could attenuate this drug-induced injury by measuring cardiac function and fibrosis.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice given pegylated liposomal doxorubicin, Tβ4 did not significantly influence myocardial fibrosis.

    In plain wordsIn mice with drug-induced heart injury, Tβ4 did not significantly change scarring of the heart muscle.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeMyocardial fibrosis
    Study

    mousen: not reported in source

    mice with doxorubicin-induced cardiac injury
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    did not significantly influence myocardial fibrosis.
    1 context sentence
    Summary · context
    Thymosin beta 4 is a peptide with cardioprotective, anti-oxidant and anti-fibrotic properties and we further investigated whether the peptide could attenuate this drug-induced injury by measuring cardiac function and fibrosis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.